122 related articles for article (PubMed ID: 37951357)
1. A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.
Uno K; Rastegar B; Jansson C; Durand G; Valind A; Chattopadhyay S; Bertolotti A; Ciceri S; Spreafico F; Collini P; Perotti D; Mengelbier LH; Gisselsson D
Mod Pathol; 2024 Jan; 37(1):100382. PubMed ID: 37951357
[TBL] [Abstract][Full Text] [Related]
2. Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution.
Rastegar B; Andersson N; Petersson A; Karlsson J; Chattopadhyay S; Valind A; Jansson C; Durand G; Romerius P; Jirström K; Holmquist Mengelbier L; Gisselsson D
Clin Cancer Res; 2023 Jul; 29(14):2668-2677. PubMed ID: 37140929
[TBL] [Abstract][Full Text] [Related]
3. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
[TBL] [Abstract][Full Text] [Related]
4. Bilateral wilms tumor with TP53-related anaplasia.
Popov SD; Vujanic GM; Sebire NJ; Chagtai T; Williams R; Vaidya S; Pritchard-Jones K
Pediatr Dev Pathol; 2013; 16(3):217-23. PubMed ID: 23387809
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
[TBL] [Abstract][Full Text] [Related]
8. Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group.
Faria P; Beckwith JB; Mishra K; Zuppan C; Weeks DA; Breslow N; Green DM
Am J Surg Pathol; 1996 Aug; 20(8):909-20. PubMed ID: 8712292
[TBL] [Abstract][Full Text] [Related]
9. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
Bardeesy N; Beckwith JB; Pelletier J
Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
[TBL] [Abstract][Full Text] [Related]
10. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
[TBL] [Abstract][Full Text] [Related]
11. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
12. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
[TBL] [Abstract][Full Text] [Related]
13. Association of TP53 polymorphisms on the risk of Wilms tumor.
Andrade RC; Cardoso LC; Ferman SE; Faria PS; Seuánez HN; Achatz MI; Vargas FR
Pediatr Blood Cancer; 2014 Mar; 61(3):436-41. PubMed ID: 24038938
[TBL] [Abstract][Full Text] [Related]
14. Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia.
Schiavetti A; Varrasso G; Collini P; Clerico A
J Pediatr Hematol Oncol; 2018 May; 40(4):331-333. PubMed ID: 28859044
[TBL] [Abstract][Full Text] [Related]
15. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
[TBL] [Abstract][Full Text] [Related]
16. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
[TBL] [Abstract][Full Text] [Related]
18. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
